Athersys Inc (NQ: ATHX )
0.8581 USD +0.0618 (+7.76%) Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2022 Add to My Watchlist
Press releases about Athersys Inc
Athersys to Host a Virtual Presentation on Its MultiStem® Programs
January 26, 2022
Athersys event will provide an understanding of the expected program milestones and why the Company is well-positioned to deliver on its mission.
Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer
January 20, 2022
New Athersys CEO Dan Camardo brings extensive market launch experience to lead the Company forward on its path to commercialization.
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Tags Featured News
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
November 30, 2021
Publication of Athersys clinical trial results show MultiStem cell therapy support potential benefits for ARDS patients, including lower mortality.
Positive topline data for ARDS study announced and countdown begins to the release of pivotal stroke study data for MultiStem cell therapy.
Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
November 12, 2021
Athersys reports its partner Healios provided an update regarding its clinical programs for ARDS and ischemic stroke involving MultiStem cell therapy.
Athersys to Host Third Quarter Financial Results Call
October 18, 2021
Athersys, a late-stage clinical company developing MultiStem cell therapy, will be participating in two events at the Cell & Gene Meeting on the Mesa.
Tags Featured News
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
August 10, 2021
Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.
Athersys Reports Second Quarter 2021 Results
August 09, 2021
Athersys reports Q2 earnings and positive topline ARDS data evaluating MultiStem® from its partner HEALIOS, K.K. The companies advance partnership.
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study
August 06, 2021
Healios announces positive topline clinical data from the ONE-BRIDGE study evaluating MultiStem for acute respiratory distress syndrome (ARDS).
Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership
August 05, 2021
Healios and Athersys deepen their partnership and improve the collaboration agreement to enhance preparations for commercial activity in Japan.
Athersys to Host Second Quarter Financial Results Call
July 13, 2021
New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications
June 30, 2021
Peer-reviewed publication provides evidence of MAPC / MultiStem mechanisms of action on the inflammatory response by promoting Treg differentiation.
Athersys Reports First Quarter 2021 Results
May 06, 2021
Athersys reports First Quarter 2021 financial results and will provide a corporate update today at 4:30 PM EDT.
Ivor Macleod, CFO of Athersys Inc. is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 12th.
Athersys to Host First Quarter Financial Results Call
April 13, 2021
Athersys, Inc. will host its first quarter 2021 financial results call on Thursday, May 6, 2021 at 4:30 PM EDT.
Athersys will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14th and the event will be webcast.
Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Distress Syndrome in Japan
March 31, 2021
Athersys partner in Japan, HEALIOS KK, completes enrollment in the ONE-BRIDGE study evaluating MulitiStem cell therapy for the treatment of ARDS.
Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.
Athersys to Host Year-End 2020 Financial Results Call
March 02, 2021
Athersys Announces Cooperation Agreement With HEALIOS K.K.
February 16, 2021
Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.
Athersys Announces CEO Transition
February 16, 2021
Athersys to Host a Virtual Investor Day
January 28, 2021
Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
December 21, 2020
UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries
Athersys Announces Three Appointments to Board of Directors
November 16, 2020
Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.
Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications